| Statement |
1.Name and nature of the subject matter (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g.dividend yield):
Common shares of Corpus Christi Polymers, LLC
2.Date of occurrence of the event:2019/01/31
3.Volume, unit price, and total monetary amount of the transaction:
Transaction volume: N/A
Price per unit: N/A
Total purchase price: US$ 33,333,333.33
4.Counterpart to the trade and its relationship to the Company (if the trading counterpart is a natural person and furthermore is not
an actual related party of the Company, the name of the trading counterpart is not required to be disclosed):
Trading counterpart : Corpus Christi Polymers, LLC
Relationship with the company : the investee under the equity method
5.Where the counterpart to the trade is an actual related party, a public announcement shall also be made of the reason for choosing
the related party as trading counterpart and the identity of the previous owner (including its relationship with the company and
the trading counterpart), price of transfer, and date of acquisition:
Capital injection / NIL
6.Where a person who owned the property within the past five years has been an actual related person of the company, a public
announcement shall also include the dates and prices of acquisition and disposal by the related person and the person’s
relationship to the company at those times:N/A
7.Matters related to the creditor's rights currently being disposed of (including types of collateral of the disposed creditor's rights;
if the creditor's rights are creditor's rights toward a related person, the name of the related person and the book amount
of the creditor's rights toward such related person currently being disposed of must also be announced):N/A
8.Anticipated profit or loss from the disposal (not applicable in cases of acquisition of securities) (where originally deferred,
the status or recognition shall be stated and explained):N/A
9.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract,
and other important stipulations:
Cash / NIL / NIL
10.The manner in which the current transaction was decided, the reference basis for the decision on price,
and the decision-making department: Capital injection / Capital injection / The BOD
11.Current cumulative volume, amount, and shareholding percentage of holdings of the security being traded
(including the current trade) and status of any restriction of rights (e.g.pledges):
N/A / NT$ 12,810,798,000 / 33.33% / NIL
12.Current ratio of long or short term securities investment (including the current trade) to the total assets and shareholder's equity
as shown in the most recent financial statement and the operating capital as shown in the most recent financial statement:
Current ratio to total assets: 5.49%
Current ratio to shareholders’ equity: 8.08%
The operating capital as shown in the most recent financial statement: NT$ 8,061,699,000
13.Broker and broker's fee:N/A
14.Concrete purpose or use of the acquisition or disposal: To increase investment in the U.S.
15.Net worth per share of the underlying securities acquired or disposed of: N/A
16.Do the directors have any objection to the present transaction?:NIL
17.Has the CPA issued an opinion on the unreasonableness of the price of the current transaction?: No
18.Any other matters that need to be specified:NIL
|
